SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: Cacaito who wrote (865)11/22/1997 11:27:00 AM
From: Myron David Kor  Read Replies (1) | Respond to of 7041
 
Did Amgen, Xoma, Scios, publish all their data from phase III studies?



To: Cacaito who wrote (865)11/22/1997 12:13:00 PM
From: Tunica Albuginea  Read Replies (1) | Respond to of 7041
 
Cacaito, is it possible that the reason Zonagen has not published any studies so far is that they have zero data to publish in a reputable
medical journal? Your opinion appreciated. ggg

TA



To: Cacaito who wrote (865)11/22/1997 11:00:00 PM
From: BigKNY3  Read Replies (1) | Respond to of 7041
 
Cacaito <<Xoma has dozens of articles (if not hundreds) on their E5 and BPI products, both at least 1 year away from approval>>

Cacaito: You make a good point. It also depends on the product being studied. For example, E-5 has been studied for almost 10 years. At some point, some of these studies get completed. However, for the ED products, most studies became less than 2 years ago.

BigKNY3


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News